Open AccessVitamin D<sub>3</sub> Treatment Decreases Frequencies of CD16-Positive and TNF-α-Secreting Monocytes in Asthmatic Patients
Author(s) -
Kamil Grubczak,
Danuta Lipińska,
Andrzej Eljaszewicz,
Paulina Singh,
Urszula Radzikowska,
Paula Mikłasz,
Milena Dąbrowska,
Ewa Jabłońska,
Anna Bodzenta-Łukaszyk,
Marcin Moniuszko
Publication year - 2015
Publication title -
international archives of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.696
H-Index - 100
eISSN - 1423-0097
pISSN - 1018-2438
DOI - 10.1159/000380882
Subject(s) - medicine , vitamin d and neurology , endocrinology , cytokine , flow cytometry , glucocorticoid , immunology , microbiology and biotechnology , biology
Previously, we demonstrated that glucocorticoid (GC) treatment of asthmatic patients resulted in decreasing frequencies of monocyte subsets expressing CD16 and capable of releasing TNF-α. Here, we wished to analyze whether the active form of vitamin D, i.e. vitamin D3, referred to as 1α,25-dihydroxyvitamin D3 [1,25-(OH)2D3] can exert GC-like proapoptotic effects on CD16-positive monocytes and thus decrease the proinflammatory potential of these cells. Finally, we set out to investigate whether the addition of 1,25-(OH)2D3 would facilitate the use of lower doses of GC without decreasing their anti-inflammatory properties.